| 產(chǎn)品編號(hào) | bsm-62268R |
| 英文名稱 | GSK3A Recombinant Rabbit mAb |
| 中文名稱 | 糖原合酶激酶3α重組兔單抗 |
| 別 名 | GSK 3 alpha; GSK 3A; GSK-3 alpha; Gsk3a; GSK3alpha. |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Recombinant |
| 克 隆 號(hào) | |
| 交叉反應(yīng) | Human,Mouse,Rat |
| 產(chǎn)品應(yīng)用 | WB=1:1000-1:2000,IHC-P=1:100-1:200,IHC-F=1:100-1:200,IF=1:50-1:200,ICC/IF=1:50-1:200,IP=1:20-1:50
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 51 kDa |
| 檢測(cè)分子量 | 51 |
| 性 狀 | Liquid |
| 免 疫 原 | A synthesized peptide derived from human GSK 3 alpha: 50-100 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol. |
| 保存條件 | Store at 4℃ for short term. Store at -20℃ for long term. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
Constitutively active protein kinase that acts as a negative regulator in the hormonal control of glucose homeostasis, Wnt signaling and regulation of transcription factors and microtubules, by phosphorylating and inactivating glycogen synthase (GYS1 or GYS2), CTNNB1/beta-catenin, APC and AXIN1.Requires primed phosphorylation of the majority of its substrates. SWISS: P49840 Gene ID: 2931 組成性活性蛋白激酶，通過(guò)磷酸化和失活糖原合成酶（GYS1或GYS2）、CTNNB1/β連環(huán)蛋白、APC和AXIN1，在激素控制葡萄糖穩(wěn)態(tài)、Wnt信號(hào)傳導(dǎo)和轉(zhuǎn)錄因子及微管的調(diào)節(jié)中作為負(fù)調(diào)節(jié)因子。它的大多數(shù)底物需要啟動(dòng)磷酸化。通過(guò)磷酸化和抑制GYS1活性從而促進(jìn)糖原合成的胰島素調(diào)節(jié)。調(diào)節(jié)肝臟的糖原代謝，而不是肌肉。也可能通過(guò)調(diào)節(jié)轉(zhuǎn)錄因子的激活來(lái)介導(dǎo)胰島素抵抗的發(fā)展。在Wnt信號(hào)中，調(diào)節(jié)核CTNNB1/β連環(huán)蛋白的水平和轉(zhuǎn)錄活性。促進(jìn)淀粉樣前體蛋白（APP）的加工和阿爾茨海默病APP源性淀粉樣斑塊的形成?？赡軈? |
| 產(chǎn)品圖片 |
Western blot analysis of HeLa cell lysate. Using GSK3A (bsm-62268R) monoclonal antibody at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
|
